HRP20220837T1 - Terapeutski pripravci koji sadrže deuterirane ili djelomično deuterirane n,n-dimetiltriptaminske spojeve - Google Patents
Terapeutski pripravci koji sadrže deuterirane ili djelomično deuterirane n,n-dimetiltriptaminske spojeve Download PDFInfo
- Publication number
- HRP20220837T1 HRP20220837T1 HRP20220837TT HRP20220837T HRP20220837T1 HR P20220837 T1 HRP20220837 T1 HR P20220837T1 HR P20220837T T HRP20220837T T HR P20220837TT HR P20220837 T HRP20220837 T HR P20220837T HR P20220837 T1 HRP20220837 T1 HR P20220837T1
- Authority
- HR
- Croatia
- Prior art keywords
- dimethyltryptamine
- pharmaceutically acceptable
- prothio
- dideutero
- deutero
- Prior art date
Links
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical class C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 title claims 12
- 239000000203 mixture Substances 0.000 title claims 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 15
- DMULVCHRPCFFGV-BNEYPBHNSA-N 1-deuterio-2-(1H-indol-3-yl)-N,N-dimethylethanamine Chemical compound [2H]C(Cc1c[nH]c2ccccc12)N(C)C DMULVCHRPCFFGV-BNEYPBHNSA-N 0.000 claims 6
- -1 α-deutero-N,N-dimethyltryptamine compound Chemical class 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical group OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000001671 psychotherapy Methods 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (14)
1. Pripravak koji sadrži: (a) α,α-dideutero-N,N-dimetiltriptaminski spoj, ili njegovu farmaceutski prihvatljivu sol; (b) α-protio, α-deutero-N,N-dimetiltriptaminski spoj, ili njegova farmaceutski prihvatljiva sol; i (c) N,N-dimetiltriptamin, ili njegove farmaceutski prihvatljive soli;
pri čemu pripravak sadrži 50% ili više po težini spoja α,α-dideutero-N,N-dimetiltriptamina, ili njegove farmaceutski prihvatljive soli, i α-protio, α-deutero-N,N-dimetiltriptaminskog spoja, ili njegove farmaceutski prihvatljive soli.
2. Pripravak prema zahtjevu 1, koji se uglavnom sastoji od:
a) α,α-dideutero-N,N-dimetiltriptamin, ili njegove farmaceutski prihvatljive soli;
(b) α-protio, α-deutero-N,N-dimetiltriptamin, ili njegove farmaceutski prihvatljive soli; i
(c) N,N-dimetiltriptamin, ili njegove farmaceutski prihvatljive soli;
pri čemu je srednja molekularna težina α-protio, α-deutero-N,N-dimetiltriptamina, α,α-dideutero-N,N-dimetiltriptamina i N,N-dimetiltriptamina, prisutnih u pripravku od 188.90 do 190.28.
3. Pripravak prema zahtjevu 1 ili zahtjevu 2 sadrži 60% ili više po težini α,α-dideutero-N,N-dimetiltriptaminskog spoja, ili njegove farmaceutski prihvatljive soli, i α-protio, α-deutero-N,N -dimetiltriptaminski spoj, ili njegove farmaceutski prihvatljiva soli.
4. Pripravak prema bilo kojem od zahtjeva 1 do 3 naznačen time što je α,α-dideutero-N,N-dimetiltriptaminski spoj α,α-dideutero-N,N-dimetiltriptamin, ili njegova farmaceutski prihvatljiva sol.
5. Pripravak prema bilo kojem od zahtjeva 1, 3 i 4 sadrži α-protio, α-deutero-N,N-dimetiltriptaminski spoj odabran iz skupine koju čine α,β,β-trideutero-N,N-dimetiltriptamin, α,β-dideutero-N,N-dimetiltriptamin, i α-protio, α-deutero-N,N-dimetiltriptamin, i njihove farmaceutski prihvatljive soli.
6. Pripravak prema bilo kojem od zahtjeva 1 do 5 sadrži α-protio, α-deutero-N,N-dimetiltriptamin, ili njegovu farmaceutski prihvatljivu sol.
7. Pripravak prema bilo kojem od zahtjeva 1 do 6 koji ima čistoću veću ili jednaku 99% prema HPLC, poželjno čistoću veću ili jednaku 99.9% prema HPLC.
8. Pripravak prema bilo kojem od zahtjeva 1 do 7, naznačen time što su α-protio, α-deutero-N,N-dimetiltriptamin i α,α-dideutero-N,N-dimetiltriptamin spojevi, i N,N-dimetiltriptamin, u obliku farmaceutski prihvatljive soli, poželjno gdje je farmaceutski prihvatljiva sol fumaratna sol.
9. Pripravak prema bilo kojem od zahtjeva 1 do 7, naznačen time što su α-protio, α-deutero-N,N-dimetiltriptamin i α,α-dideutero-N,N-dimetiltriptamin spojevi, i N,N-dimetiltriptamin, u obliku fumaratne soli.
10. Pripravak kako je definiran u bilo kojem od zahtjeva 1 do 9 za uporabu u terapiji.
11. Pripravak kako je definiran u bilo kojem od zahtjeva 1 do 9 za uporabu u liječenju psihokognitivnog poremećaja kod pacijenata.
12. Pripravak za uporabu prema zahtjevu 11 naznačen time što je psihokognitivni poremećaj odabran iz skupine koja se sastoji od (i) opsesivno kompulzivnog poremećaja, (ii) depresivnog poremećaja, (iii) anksioznog poremećaja, (iv) zlouporabe tvari, i (v) poremećaja volje.
13. Pripravak za uporabu prema zahtjevu 12, naznačen time što je poremećaj veliki depresivni poremećaj, poželjno je da je poremećaj depresija otporna na liječenje.
14. Pripravak kako je definiran u bilo kojem od zahtjeva 1 do 9, za uporabu u psihoterapiji potpomognutoj dimetiltriptaminom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1907871.6A GB201907871D0 (en) | 2019-06-03 | 2019-06-03 | Therapeutic compositions |
| PCT/EP2020/065244 WO2020245133A1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| EP20731372.7A EP3826632B1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20220837T1 true HRP20220837T1 (hr) | 2022-10-14 |
| HRP20220837T8 HRP20220837T8 (hr) | 2023-02-03 |
Family
ID=67385960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220837TT HRP20220837T8 (hr) | 2019-06-03 | 2020-06-02 | Terapeutski pripravci koji sadrže deuterirane ili djelomično deuterirane n,n-dimetiltriptaminske spojeve |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20220168275A1 (hr) |
| EP (2) | EP4062910A1 (hr) |
| JP (1) | JP2022535093A (hr) |
| KR (1) | KR20220034061A (hr) |
| CN (1) | CN114096246A (hr) |
| AU (1) | AU2020286709B2 (hr) |
| BR (1) | BR112021024333A2 (hr) |
| CA (2) | CA3142290A1 (hr) |
| DK (1) | DK3826632T3 (hr) |
| EA (1) | EA202193338A1 (hr) |
| ES (1) | ES2922101T3 (hr) |
| GB (4) | GB201907871D0 (hr) |
| HR (1) | HRP20220837T8 (hr) |
| HU (1) | HUE059439T2 (hr) |
| IL (1) | IL288617A (hr) |
| MX (1) | MX2021014728A (hr) |
| PL (1) | PL3826632T3 (hr) |
| PT (1) | PT3826632T (hr) |
| TW (1) | TW202210075A (hr) |
| WO (1) | WO2020245133A1 (hr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| WO2021089872A1 (en) | 2019-11-07 | 2021-05-14 | Small Pharma Ltd | Compounds |
| WO2021155467A1 (en) | 2020-02-04 | 2021-08-12 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| CN115397810A (zh) | 2020-02-04 | 2022-11-25 | 明德赛特制药公司 | 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物 |
| CA3177454A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
| CA3179161C (en) * | 2020-06-02 | 2023-10-31 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| GB2605144A (en) * | 2021-03-22 | 2022-09-28 | Small Pharma Ltd | Deuterated compounds |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| AU2021391581A1 (en) | 2020-12-01 | 2023-07-06 | Cybin Uk Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| WO2022120181A1 (en) | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| CN117242065A (zh) * | 2021-03-02 | 2023-12-15 | 明德赛特制药公司 | 作为血清素能药物的用于治疗与之相关的疾病的吲哚衍生物 |
| BR112023022195A2 (pt) * | 2021-04-26 | 2024-01-16 | Atai Therapeutics Inc | Novas composições e métodos de n,n-dimetiltriptamina |
| JP2024516279A (ja) * | 2021-05-05 | 2024-04-12 | カレ ケミカル テクノロジーズ インコーポレイテッド | 触媒トリプタミンプロセスおよび前駆体 |
| AU2022277515A1 (en) * | 2021-05-17 | 2023-10-19 | Cybin Irl Limited | Formulations of psilocybin |
| KR20240017363A (ko) * | 2021-06-02 | 2024-02-07 | 세인트 조셉스 유니버시티 | 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법 |
| IL310378A (en) | 2021-08-12 | 2024-03-01 | Kuleon Llc | Serotonin receptor agonists that cause hallucinations and that do not cause hallucinations and methods for their preparation and use |
| WO2023028091A1 (en) * | 2021-08-23 | 2023-03-02 | Alexander Shulgin Research Institute | Deuterated empathogens |
| IL311051A (en) * | 2021-08-23 | 2024-05-01 | Alexander Shulgin Res Institute Inc | Fluorinated empathogens |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| EP4159201A1 (en) * | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| WO2023076135A1 (en) * | 2021-10-29 | 2023-05-04 | Psilera Inc. | N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same |
| WO2023089132A1 (en) | 2021-11-18 | 2023-05-25 | Small Pharma Ltd | Injectable and inhalable formulations |
| WO2023186867A1 (en) * | 2022-03-31 | 2023-10-05 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| EP1292282A2 (en) | 2000-06-16 | 2003-03-19 | RTP Pharma Inc. | Improved injectable dispersions of propofol |
| WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| EP2081893B1 (en) | 2006-10-19 | 2011-03-23 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
| US20090093513A1 (en) | 2007-10-09 | 2009-04-09 | Hamann Mark T | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter |
| WO2018148605A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| WO2018195455A1 (en) | 2017-04-20 | 2018-10-25 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
| CN114555078A (zh) | 2019-02-22 | 2022-05-27 | Gh研究爱尔兰有限公司 | 用于治疗抑郁症的5-甲氧基-n,n-二甲基色胺(5-meo-dmt) |
| PE20220001A1 (es) | 2019-02-22 | 2022-01-05 | Gh Res Ireland Limited | Composiciones que comprenden 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales |
| BR112021016620A2 (pt) | 2019-02-27 | 2021-11-03 | Univ California | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais |
| JP2022523774A (ja) | 2019-02-27 | 2022-04-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物 |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| WO2021089872A1 (en) | 2019-11-07 | 2021-05-14 | Small Pharma Ltd | Compounds |
| CN115397810A (zh) | 2020-02-04 | 2022-11-25 | 明德赛特制药公司 | 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物 |
| CA3177454A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| CA3188263A1 (en) | 2020-08-05 | 2022-02-10 | Matthias Emanuel LIECHTI | Intravenous dmt administration method for dmt-assisted psychotherapy |
| AU2021334933B2 (en) | 2020-08-28 | 2023-01-19 | Cybin Uk Ltd | Injectable formulation |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| WO2022069690A2 (en) | 2020-10-02 | 2022-04-07 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2019
- 2019-06-03 GB GBGB1907871.6A patent/GB201907871D0/en not_active Ceased
-
2020
- 2020-06-02 ES ES20731372T patent/ES2922101T3/es active Active
- 2020-06-02 CA CA3142290A patent/CA3142290A1/en active Pending
- 2020-06-02 EP EP22173907.1A patent/EP4062910A1/en active Pending
- 2020-06-02 JP JP2021571882A patent/JP2022535093A/ja active Pending
- 2020-06-02 GB GB2100807.3A patent/GB2586940B/en active Active
- 2020-06-02 HU HUE20731372A patent/HUE059439T2/hu unknown
- 2020-06-02 DK DK20731372.7T patent/DK3826632T3/da active
- 2020-06-02 PT PT207313727T patent/PT3826632T/pt unknown
- 2020-06-02 PL PL20731372.7T patent/PL3826632T3/pl unknown
- 2020-06-02 EA EA202193338A patent/EA202193338A1/ru unknown
- 2020-06-02 US US17/616,345 patent/US20220168275A1/en active Pending
- 2020-06-02 GB GB2008303.6A patent/GB2585978B/en active Active
- 2020-06-02 HR HRP20220837TT patent/HRP20220837T8/hr unknown
- 2020-06-02 BR BR112021024333A patent/BR112021024333A2/pt unknown
- 2020-06-02 WO PCT/EP2020/065244 patent/WO2020245133A1/en unknown
- 2020-06-02 EP EP20731372.7A patent/EP3826632B1/en active Active
- 2020-06-02 GB GB2107702.9A patent/GB2592822B/en active Active
- 2020-06-02 MX MX2021014728A patent/MX2021014728A/es unknown
- 2020-06-02 US US16/890,664 patent/US11771681B2/en active Active
- 2020-06-02 KR KR1020217043410A patent/KR20220034061A/ko not_active IP Right Cessation
- 2020-06-02 AU AU2020286709A patent/AU2020286709B2/en active Active
- 2020-06-02 CN CN202080050439.9A patent/CN114096246A/zh active Pending
- 2020-12-23 CA CA3104072A patent/CA3104072C/en active Active
-
2021
- 2021-06-01 TW TW110119792A patent/TW202210075A/zh unknown
- 2021-12-02 IL IL288617A patent/IL288617A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220837T1 (hr) | Terapeutski pripravci koji sadrže deuterirane ili djelomično deuterirane n,n-dimetiltriptaminske spojeve | |
| HRP20201946T1 (hr) | Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutski sastavi, postupci liječenja, i postupak za dobivanje modulatora | |
| HRP20191285T1 (hr) | Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti | |
| HRP20191477T1 (hr) | Farmaceutski sastav s-ketamin hidroklorida | |
| HRP20220295T1 (hr) | Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| HRP20210090T1 (hr) | Farmaceutski pripravak koji sadrži nikotinsku kiselinu i/ili nikotinamid i/ili triptofan za pozitivan uticaj na crijevnu mikrobiotu | |
| HRP20221106T1 (hr) | Postupci liječenja abnormalnih nevoljnih poremećaja pokreta | |
| JP2019524690A5 (hr) | ||
| JP2015038135A5 (hr) | ||
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| HRP20221325T1 (hr) | Pripravci i postupci transmukozne apsorpcije | |
| HRP20221495T1 (hr) | Farmaceutske kompozicije koje sadrže derivate imidazotiadiazola i imidazopiridazina kao inhibitore proteazom aktiviranih receptora 4 (par4) za liječenje agregacije trombocita | |
| HRP20221269T1 (hr) | Pripravci za liječenje mijelofibroze | |
| HRP20121034T1 (hr) | Lijeäśenje upalnih bolesti | |
| HRP20160403T1 (hr) | Liječenje lipodistrofije | |
| HRP20191175T1 (hr) | Spojevi koji su inhibitori signaliziranja u notch putu | |
| HRP20121033T1 (hr) | Praškasta formulacija za valganciklovir | |
| BR112013031406A2 (pt) | forma de dosagem oral comestível em tira ou disco contendo resina de troca iônica para mascarar o sabor | |
| HRP20140773T1 (hr) | Farmaceutska kompozicija protiv malarije | |
| WO2019236775A8 (en) | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | |
| HRP20200423T1 (hr) | Kombinirana terapija | |
| HRP20150711T1 (hr) | Tretiranje kognitivnih poremeä†aja (r)-7-klor-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima | |
| EA201590933A1 (ru) | Новые перорально биодоступные соединения, модулирующие контроль дыхания, и способы их использования | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika |